The story of how Novo Nordisk will lose billions because it didn't pay a couple of hundred dollars

Novo Nordisk is set to lose patent protection for Ozempic in Canada due to a missed $250 maintenance fee in 2019, potentially costing the company billions as generic versions from companies like Sandoz, Hikma Pharmaceuticals, and Aspen Pharmaceuticals enter the market. Canadian retail sales of Ozempic totaled $2.5 billion last year, making it the top-selling drug in the country, and the lapse raises the possibility of importing cheaper generics into the U.S. under Section 804 importation programs, with Florida currently in discussions with the FDA.

Analysis

Novo Nordisk (NVO) faces a significant financial challenge due to the impending premature loss of patent protection for its leading drug, Ozempic, in Canada, effective 2026. This situation arose from an administrative oversight in 2019 when the company failed to pay a C$250 annual patent maintenance fee. The financial implications are substantial, as Ozempic generated C$2.5 billion in Canadian retail pharmacy sales last year, establishing it as the country's top-selling drug, and contributed to its $19 billion in global sales. This early patent expiry will expose Novo Nordisk to generic competition in Canada sooner than anticipated, with companies like Sandoz, Hikma Pharmaceuticals, and Aspen Pharmaceuticals already filing to produce generic versions of semaglutide. A further material risk stems from the potential importation of these Canadian generics into the U.S. market under the Section 804 importation program; Florida is currently in dialogue with the Food and Drug Administration regarding such a program. The strongly negative sentiment score of -0.75 for the event and -0.8 specifically for NVO, coupled with a market impact score of 0.7, underscores the perceived severity of this oversight and its potential to erode a key revenue stream for Europe's largest company by market capitalization.

Key Decisions for Investors

• Investors should adjust future revenue projections for Novo Nordisk's Ozempic to account for accelerated generic competition in Canada from 2026 and the potential for erosion of its C$2.5 billion annual Canadian sales.
• Closely monitor developments regarding the U.S. Section 804 importation program, particularly Florida's discussions with the FDA, as the introduction of Canadian generics into the U.S. could significantly impact Ozempic's larger market share and pricing power.
• Re-evaluate the risk associated with Novo Nordisk's intellectual property management practices, considering the substantial financial consequences of this administrative lapse on a blockbuster drug, and its potential implications for the company's broader patent portfolio.